EMPEROR-Preserved Trial

Dr. Charmaine Lam will presented the EMPEROR-Preserved Trial, which is a double-blind, randomized control trial comparing the use of empagliflozin (10mg) to placebo among patients with class II–IV heart failure and an ejection fraction of more than 40% looking at the primary composite outcome of cardiovascular death or hospitalization for heart failure.